|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||91.69 - 93.00|
|52 Week Range||78.42 - 100.51|
|PE Ratio (TTM)||-85.75|
|Earnings Date||Oct 25, 2017 - Oct 30, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||111.57|
The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.
These three orphan drugmakers were on Soros' radar last quarter.
Regulatory Review Process Proceeding In-line with Company's Expectations SAN RAFAEL, Calif. , Sept. 14, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food ...